Measles virus antibody responses in children randomly assigned to receive standard-titer Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age, 9 months of age, or 9 and 18 months of age

Journal of Infectious Diseases

Volumn 210, Issue 5, 2014, Pages 693-700

  Martins, Cesario ^a   Garly, May Lill ^a   Bale, Carlitos ^a   Rodrigues, Amabelia ^a   Njie Jobe, Jainaba ^c   Benn, Christine S ^a,b   Whittle, Hilton ^c   Aaby, Peter ^a,b  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b STATENS SERUM INSTITUT   (Denmark)

^c MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

Author keywords

Antibody response; Early measles vaccination; Edmonston Zagreb measles vaccine; Non specific effects of vaccines; Two dose measles vaccination

Indexed keywords

MEASLES ANTIBODY; MEASLES VACCINE;

AGE DISTRIBUTION; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD ANALYSIS; CHILD; CONTROL STRATEGY; CONTROLLED STUDY; EARLY INTERVENTION; FEMALE; HUMAN; INFANT; INFECTION CONTROL; INFECTION PREVENTION; MALE; MEASLES; MEASLES VACCINATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEASONAL VARIATION;

ANTIBODY RESPONSE; EARLY MEASLES VACCINATION; EDMONSTON-ZAGREB MEASLES VACCINE; NON-SPECIFIC EFFECTS OF VACCINES; TWO-DOSE MEASLES VACCINATION;

AGE FACTORS; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MEASLES VACCINE; MEASLES VIRUS; VACCINATION;

EID: 84907424658     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu117     Document Type: Article

References (29)

1. Expanded Programme on Immunization. Safety of high titre measles vaccines. Wkly Epidemiol Rec 1992; 67:357-61.
2. Rosenthal SR, Clements CJ. Two-dose measles vaccination schedules. Bull World Health Organ 1993; 71:421-8.
3. George K, Joseph A, Muliyil J, Abraham S, Bhattacharji S, John KR. Measles vaccination before nine months. Trop Med Int Health 1998; 3:751-6.
4. Garly ML, Martins CL, Balé C, et al. Early two-dose measles vaccination schedule in Guinea-Bissau: Good protection and coverage in infancy. Int J Epidemiol 1999; 28:347-52.
5. Garly ML, Martins CL, Balé C, et al. Measles antibody responses after early two doses trials in Guinea-Bissau with Edmonston-Zagreb and Schwartz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 2001; 19:1951-9.
6. Sabin AB, Arechiga AF, Valdespino JL. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984; 249:2651-2.
7. Khanum S, Uddin N, Garelick H, Mann G, Tomkins A. Comparison of Edmonston-Zagreb and Schwarz strains of measles vaccine given by aerosol or subcutaneous injection. Lancet 1987; ii:150-3.
8. Markowitz LE, Bernier RH. Immunization of young infants with Edmonston- Zagreb measles vaccine. Pediatr Infect Dis J 1987; 6:809-12.
9. De Quadros CA, Olive JM, Hersh BS, et al. Measles elimination in the Americas. Evolving strategies. JAMA 1996; 275:224-9.
10. Zanetta RA, Amaku M, Azevedo RS, Zametta DM, Buranttini MN, Massad E. Opimal age for vaccination against measles in the State of São Paulo, Brazil, taking into account the mother's serostatus. Vaccine, 2001; 20:226-34.
11. Martins CL, Garly ML, Balé C, et al. Protective efficacy of standard Edmonston- Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008; 337:a661;epub.
12. Aaby P, Samb B, Simondon F, Coll Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries. Br Med J 1995; 311:481-5.
13. Aaby P, Garly ML, Balé C, et al. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: An unplanned study. Pediatr Infect Dis J 2003; 22:798-805.
14. Aaby P, Garly ML, Jensen H, et al. Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: Observations from vaccination trials in Guinea-Bissau. Pediatr Infect Dis J 2007; 26:247-52.
15. Aaby P, Martins CL, Garly ML, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: Randomised controlled trial. BMJ 2010; 341:c6495.
16. Martins C, Garly ML, Bale C, et al. Measles antibodies levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: A serological study within a randomized trial of different measles vaccines. Vaccine 2013; 31:5766-71.
17. da Silva ZJ, Oliveira I, Andersen A, et al. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau. Is HIV-2 disappearing? AIDS 2008; 22:1195-202.
18. Whittle H, Campbell H, Rahman S, Armstrong JRM. Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine. Lancet 1990; 336:1048-51.
19. Norrby E. Hemagglutination by measles virus. Proc Soc Exp Biol Med 1962; 111:814-8.
20. Samb B, Aaby P, Whittle H, et al. Serological status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 1995; 14:203-9.
21. Lubin JH, Colt JS, Camann D, et al. Epidemiologic evaluation of measurement data in the presence of detection limits. Environ Health Perspect 2004; 112:1691-6.
22. Martins C, Bale C, Garly ML, et al. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. Vaccine 2009; 27:5220-5.
23. Siegrist CA, Barrios C, Martinez X, et al. Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell response allow successful early prime-boost strategies in mice. Eur J Immunol 1998; 28:4138-48.
24. Aaby P, Benn CS. Assessment of childhood immunisation coverage. Lancet 2009; 373:1428.
25. Aaby P, Jensen H, Walraven G. Age-specific changes in female-male mortality ratio related to the pattern of vaccinations: An observational study from rural Gambia. Vaccine 2006; 24:4701-8.
26. Aaby P, Jensen H, Samb B, et al. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 2003; 361:2183-8.
27. Aaby P, Benn CS, Nielsen J, Lisse IM, Rodrigues A, Ravn H. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in highmortality countries. BMJ Open 2012; 2:e000707.
28. Benn CS, Aaby P. Diphtheria-tetanus-pertussis vaccination administered after measles vaccine: Increased female mortality? Pediatr Infect Dis J 2012; 31:1095-7.
29. Aaby P, Martins CL, Garly ML, Rodrigues A, Benn CS, Whittle HC. The optimal age of measles immunization in low-income countries: A secondary analysis of the assumptions underlying the current policy. BMJ Open 2012; 2:e000761.